Methods useful in the treatment of bone resorption diseases

Details Methods useful in the treatment of bone resorption diseases Methods useful in the treatment of bone resorption diseases

2006-03-28

2006-03-28

Low, Christopher S. F. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S008100, C514S102000, C514S107000, C514S108000, C514S808000, C424S601000, C424S602000, C424S632000

Reexamination Certificate

active

07018982

ABSTRACT:
The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.

REFERENCES:
patent: 3768177 (1973-10-01), Thomas
patent: 3886132 (1975-05-01), Brewer
patent: 4016314 (1977-04-01), Cowans
patent: 4105602 (1978-08-01), Colescott
patent: 4199060 (1980-04-01), Howard
patent: 4237224 (1980-12-01), Cohen
patent: 4264731 (1981-04-01), Shine
patent: 4338397 (1982-07-01), Gilbert
patent: 4366246 (1982-12-01), Riggs
patent: 4394443 (1983-07-01), Weissman
patent: 4424278 (1984-01-01), Bucovaz
patent: 4425437 (1984-01-01), Riggs
patent: 4468464 (1984-08-01), Cohen
patent: 4532207 (1985-07-01), Brewer
patent: 4546082 (1985-10-01), Kurjan
patent: 4588684 (1986-05-01), Brake
patent: 4595658 (1986-06-01), Zinder
patent: 4624926 (1986-11-01), Inouye
patent: 4690952 (1987-09-01), Kagatani
patent: 4698328 (1987-10-01), Neer et al.
patent: 4812311 (1989-03-01), Uchtman
patent: 4822609 (1989-04-01), Flora
patent: 4833125 (1989-05-01), Neer
patent: 4904584 (1990-02-01), Shaw
patent: 4994559 (1991-02-01), Moscatelli
patent: 5010010 (1991-04-01), Gautvik
patent: 5059587 (1991-10-01), Yamamoto
patent: 5118667 (1992-06-01), Adams et al.
patent: 5164368 (1992-11-01), Recker
patent: 5171670 (1992-12-01), Kronenberg
patent: 5223407 (1993-06-01), Wong
patent: 5510370 (1996-04-01), Hock
patent: 5550134 (1996-08-01), Audia et al.
patent: 5599822 (1997-02-01), Cullinan et al.
patent: 5670514 (1997-09-01), Audia et al.
patent: 5861438 (1999-01-01), MacLean et al.
patent: 5945412 (1999-08-01), Fuh et al.
patent: 6146852 (2000-11-01), Gautvik
patent: 6284730 (2001-09-01), Dietrich et al.
patent: RE37919 (2002-12-01), Kronenberg
patent: 0123544 (1984-10-01), None
patent: 0038183 (1985-07-01), None
patent: 0140864 (1990-03-01), None
patent: 0357391 (1990-03-01), None
patent: 0163406 (1991-01-01), None
patent: 0139076 (1992-07-01), None
patent: 0177343 (1992-07-01), None
patent: 0302772 (1992-09-01), None
patent: 0792639 (1997-09-01), None
patent: 0792639 (1997-09-01), None
patent: 2092596 (1982-08-01), None
patent: 2094833 (1982-09-01), None
patent: 2248550 (1992-04-01), None
patent: WO 83/01361 (1983-04-01), None
patent: WO 84/01173 (1984-03-01), None
patent: WO 86/03519 (1986-06-01), None
patent: WO 88/00206 (1988-01-01), None
patent: WO 88/03171 (1988-05-01), None
patent: WO 89/041173 (1989-05-01), None
patent: WO 90/09167 (1990-08-01), None
patent: WO 91/06564 (1991-05-01), None
patent: WO 92/09304 (1992-06-01), None
patent: WO 93/11785 (1993-06-01), None
patent: WO 93/11786 (1993-06-01), None
patent: WO 94/08613 (1994-04-01), None
patent: WO 96/07416 (1996-03-01), None
patent: WO 96/07417 (1996-03-01), None
patent: WO 96/07417 (1996-03-01), None
patent: WO 97/31640 (1997-09-01), None
patent: WO 97 31640 (1997-09-01), None
Dempster et al., “Anabolic Actions of Parathyroid Hormone on Bone,”Endocrine Reviews, Baltimore, MD, US, vol. 14, No. 6, Dec. 1, 1993, pp. 690-709, XP002056317.
Whitfield et al., “Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis,”Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, Nov. 1995, pp. 382-386, XP004207554.
Whitfield et al., “Comparison of the ability of recombinant human parathyroid hormone, rhPTH-(1-84), and hPTH-(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats,”Calcified Tissue International, New York, NY, US, Jan. 1, 1997, pp. 26-29, XP002249487.
Abstracts, ASBMR-IBMS, Second Joint Meeting, pp. S175, articles 1109-1112.
ASBMR 22ndAnnual Meeting, Received Fax: Jan. 26, 2004, 2:39PM, Fax Station: NPS Pharmaceuticals, p. 1; SU456-SU459, p. S442.
** Bagdasarian et al, “Activity of the Hybrid trp-lac(tac) Promoter ofEscherichia coliin Pseudomonas Putida. Construction of Broad-Host-Range, Controlled-Expression Vectors”, Gene, vol. 26:273-282, (1983).
** Bell et al, “Human Epidermal Growth Factor Precursor: cDNA Sequence, Expression in Vitro and Gene Organization”, Nucleic Acids Research, vol. 14:8427-8446, (1986).
Bittner et al, “Versatile Cloning Vectors Derived From The Runaway-Replication Plasmid pKN402”, Gene 15: 319-329 (1981).
Black, et al., Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches, Journal of Bone and Mineral Research, 1999, pp. 90-101, vol. 14 No. 1, Blackwell Science, Inc., USA.
** Blight et al, TIB Tech 12: 450 (1994).
** Born et al., “Expression and Processing of Human Preproparathyroid Hormone inEscherichia coli, ” Experientia, vol. 39, 1983, p. 659.
** Born et al., (Abstract) “Expression of Human Preproathyroid Hormone inE. coliand Yeast,” Calcified Tissue International, vol. 36, (Suppl. 2), 1984, 287.
** Born et al., (Abstract) “Expression of Human Preproparathyoid Hormone inE. coliand Yeast,” Calcified Tissue International, vol. 35, 1983, p. 679.
Born et al., “Signal Sequence Of Human Preproparathyoid Hormone Is Inactive In Yeast”, Journal Of Bone and Mineral Research, vol. 2, No. 4, p. 353-360, 1987.
** Brake et al., Alpha-Factor-directed synthesis and secretion of mature foreign proteins inSaccharomyces cerevisiae, Mar. 28, 1984.
Breyel et al., “Synthesis of mature human parathyroid hormone inEscherichia coli, ” Third European Congress on Biotechnology, vol. 3, 1984, p. 363-369.
** Breyel et al., (Abstract) “Synthesis of Mature Human Parathyroid Hormone inEscherichia Coli, ” Calcified Tissue international, vol. 36 (Suppl. 2), 1984, 297.
Brown, Homeostatic Mechanisms Regulating Extracellular and Intracellular Calcium Metabolism, The Parathyroids, 1994, pp. 15-54, Raven Press, Ltd.
** Cantrell et al., cDNA Cloning Expression, and Activity of Human Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Lymphokines and Their Receptors, 1987, pp. 187-205.
Castelo-Branco, et al., The effect of hormone replacement therapy on postmenopausal bone loss, European Journal of Obstetrics & Gynecology and Reproductive Biology, 1992, pp. 131-136, vol. 44, Elsevier Science Publishers B.V.
Cauley et al., Estrogen Replacement Therapy and Fractures in Older Women, Ann. Intern. Med., Jan. 1, 1995, pp. 9-16, vol. 122 No. 1, PA, USA.
** Chanj et al., Chem. Abst. vol. 92, No. 175928k, 1980 “Initiation of Protein Synthesis in Bacteria at a Translational Start Coden of Mammalian cDNA Effects of Preparathyroid Nucleotide Sequence”.
** Charbon et al Arch Int Pharmacodyn, 1968, 171(1):3 “Diuretic and vaxcular action of parathyroid extracts in animals and man”.
Cook, et al., Measuring Quality of Life in Women with Osteoporosis, Osteoporosis International, 1997, pp. 478-487, vol. 7, European Foundation for Osteoporosis and the National Osteoporosis Foundation.
Cooper, et al., Epidemiology of osteoporosis, Osteoporosis, 1996, pp. 75-77, Elsevier Science B.V.
Cosman, et al., Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal, Journal of Bone and Mineral Research, 2001, pp. 925-931, vol. 16 No. 5, American Society for bone and Mineral Research, USA.
Cranney, et al., Osteoporosis Clinical Trials Endpoints: Candidate Variables and Clinimetric Properties, The Journal of Rheumatology, 1997, pp. 1222-1229, vol. 24 No. 6, Univ. of Ottawa, Canada.
Cranney, et al., Responsiveness of Endpoints in Osteoporosis Clinical Trials—An Update, The Journal of Rheumatology, 1999, pp. 222-228, vol. 26 No. 1, Univ. of Ottawa, Canada.
Cummings, et al., Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures, JAMA, Dec. 23-30, 1998, pp. 2077-2082, vol. 280 No. 24,

Affiliated with

Also associated with

Rating

Methods useful in the treatment of bone resorption diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods useful in the treatment of bone resorption diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods useful in the treatment of bone resorption diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3587076